

Final Program

| Wednesday Oct 10, 2018 | | |
|------------------------|--|---|
| 16:00-17:00 | Registration | |
| 17:00-19:00 | Welcome Reception and Networking Event | |
| Thursday Oct 11, 2018 | | |
| Time | Topic | Confirmed Speakers |
| 7:00-8:00 | Buffet Breakfast | |
| 8:00-8:05 | Welcome and overview of PMA | Kevin Deane, MD/PhD, University of Colorado Denver and Chair, PMA |
| 8:05-8:45 | Keynote Address: THE NEXT WAVE OF PERSONALIZED MEDICINE: DISCOVER HOW DATA & AI IS TRANSFORMING PERSONALIZED/PRECISION MEDICINE | Harry Glorikian, Author of Moneyball Medicine: Thriving in the New Data-Driven Healthcare Market, and General Partner, New Ventures Funds |
| 8:45-9:15 | Integration of biomarker testing into clinical decision making | Marvin Fritzler, MD/PhD, University of Calgary |
| 9:15-9:45 | Artificial intelligence and precision medicine | Michael Mahler, PhD, Vice President of Research, Inova Diagnostics, Inc. |
| 9:45-10:15 | Coffee Break Exhibitor Hall | |
| 10:15-10:45 | Biomarker testing in diagnosis and management of early rheumatoid arthritis | Paul Emery, MD, University of Leeds, UK |
| 10:45-11:15 | Updates in biomarker and other testing in the long-term management of RA | Jeffrey Curtis, MD, MPH, University of Alabama, USA |
| 11:15 -11:45 | Emerging biomarkers in rheumatoid arthritis | Rene Toes, PhD, Leiden University Medical Center, Netherlands |
| 11:45-13:00 | Lunch Buffet Exhibitor Hall | |
| 13:00-13:30 | Synovial biopsy in rheumatoid arthritis | Costantino Pitzalis, MD/PhD, Royal London Hospital, UK |
| 13:30-14:00 | Natural history of rheumatic/autoimmune diseases in biomarker discovery | V. Michael Holers, MD, University of Colorado Denver, USA |
| 14:00-14:30 | Biomarkers and other factors in the prediction and prevention of future rheumatoid arthritis | Kevin Deane, MD/PhD, University of Colorado Denver, USA |
| 14:30-15:00 | Laboratory testing in the diagnosis and management of autoimmune lung disease | Aryeh Fischer, MD, University of Colorado Denver, USA |
| 15:00-15:30 | Coffee Break Exhibitor Hall | |
| 15:30-16:00 | Using biomarkers and other factors to more precisely estimate thrombosis risk in the antiphospholipid antibody syndrome | Michelle Petri, MD, Johns Hopkins University School of Medicine, USA |
| 16:00-16:30 | Microarray profiling of biomarkers in autoimmune disease | William Robinson, MD/PhD, Stanford University, USA |
| 16:30-17:00 | Biomarker testing in autoimmune disease: large lab perspective | Vincent Ricchiuti, PhD, Laboratory Director, LabCorp, USA |
| 17:00-17:30 | Biomarker testing in autoimmune disease: small lab perspective | Ashley Frazer-Abel, PhD, Director, ExSera Labs, University of Colorado Denver, USA |
| 17:30-17:40 | Closing remarks and reminders for Day 2 | Kevin Deane, MD/PhD, University of Colorado Denver, USA |
| | Dinner – participants on their own to explore Denver | |
| Friday Oct 12, 2018 | | |
| 7:00-8:00 | Buffet Breakfast | |
| 7:55-8:00 | Welcome and Introduction to Day 2 | Kevin Deane, MD/PhD, University of Colorado Denver, USA |



| | | |
|--------------------|--|--|
| 8:00-8:30 | Biomarker testing in the diagnosis and management of systemic lupus erythematosus | Chaim Putterman, MD, Albert Einstein College of Medicine, USA |
| 8:30-9:00 | Gene and immune signatures as a tool for the characterization of systemic lupus erythematosus | Tim Niewold, MD, Director, Colton Center for Autoimmunity, New York University, USA |
| 9:00-9:30 | Renal biopsy and precision medicine in lupus nephritis | Evan Der, PhD, Albert Einstein College of Medicine, USA |
| 9:30-10:00 | Biomarkers in CNS lupus | Sterling West, MD, University of Colorado Denver, USA |
| 10:00-10:30 | Coffee Break Exhibitor Hall | |
| 10:30-11:00 | Microbiome in the pathogenesis of systemic lupus erythematosus | Gregg Silverman, MD/PhD, New York University |
| 11:00-11:30 | The transition from incomplete lupus to lupus: opportunities for prevention | Judith James, MD/PhD, Oklahoma Medical Research Foundation, USA |
| 11:30-12:00 | Discovery of novel therapies for systemic lupus erythematosus and other autoimmune diseases | Peter Lipsky, MD, Chief Executive Officer and Chief Medical Officer, AMPEL BioSolutions |
| 12:00-13:15 | Buffett Lunch Exhibitor Hall | |
| 13:15-13:45 | Industry perspective: companion diagnostics in autoimmune disease and SLE - RNA testing | Robert Terbruggen, PhD, Founder and Chief Executive Officer, DxTerity |
| 13:45-14:15 | Industry perspective: companion diagnostics in autoimmune disease and SLE – antibodies and other markers | Thierry Dervieux, PhD, Chief Scientific Officer and Medical Laboratory Director, Exagen Diagnostics, Inc., USA |
| 14:15-14:30 | Closing remarks | Kevin Deane, MD/PhD, University of Colorado Denver, USA |



Precision
 Medicine in
 Autoimmunity

